ERBB2 and breast cancer: Overall, these results support the idea that reduced levels of CHIP, as are now known to occur in tumors such as ErbB2-overexpressing breast cancer [35,36,49], could render tumor cells more prone to ER stress and provide a basis for therapeutic targeting using clinically safe drugs with ER stress-inducing activity.